🇺🇸 FDA
Patent

US 8889661

Treatment of lupus nephritis using laquinimod

granted A61KA61K2121/00A61K2300/00

Quick answer

US patent 8889661 (Treatment of lupus nephritis using laquinimod) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2121/00, A61K2300/00, A61K31/47, A61K31/4704